Eli Lilly’s Collaboration Agreement With Evotec

Morgan Lewis represented Eli Lilly and Company on the deal.

The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec. Lilly reserves the right to select up to five programmes developed within this partnership and to continue with any subsequent development, clinical validation and commercialisation.

The collaboration initially runs for a term of three years. In addition to an undisclosed upfront payment, Evotec will be eligible to receive success-based discovery development, regulatory and commercial milestone payments of up to US$ 180 m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration, for a potential overall value up to US$ 1 bn. 

The Morgan Lewis life sciences transactions team advising Eli Lilly included partner Ben Pensak (Picture) and associate Natalie Nicelli.

Involved fees earner: Natalie Nicelli – Morgan Lewis & Bockius; Benjamin Pensak – Morgan Lewis & Bockius;

Law Firms: Morgan Lewis & Bockius;

Clients: Eli Lilly and Company;